Market Cap 1.92B
Revenue (ttm) 235.13M
Net Income (ttm) 5.75M
EPS (ttm) N/A
PE Ratio 23.17
Forward PE 17.50
Profit Margin 2.45%
Debt to Equity Ratio 0.00
Volume 1,498,900
Avg Vol 938,110
Day's Range N/A - N/A
Shares Out 131.84M
Stochastic %K 36%
Beta 1.50
Analysts Sell
Price Target $16.71

Company Profile

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement wit...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 744 2487
Fax: 250 708 4345
Address:
#140, 14315 – 118 Avenue, Edmonton, Canada
Popeye_
Popeye_ Feb. 26 at 12:36 PM
$SNAP Watchlist: $SNAP BIG NEWS: Turned into profitability last quarter. This should mark the turnaround from Snap Inc. From $5 to . https://techcrunch.com/2026/02/18/snapchat-tops-25m-subscribers-driving-companys-direct-revenue-arr-to-1b/ $IONQ Shareprice: $38 $LKNCY Shareprice: $37 $TTD Shareprice: $21 $AUPH Shareprice: $15
0 · Reply
US_Bull
US_Bull Feb. 26 at 12:35 PM
$AUPH I agree with respect to the patent litigations there is a Rule 16 telephonic conversation scheduled for March 23rd and keep in mind all the 5 litigations have been bundled up into 1 case. During or after a Rule 16 phone conversation, settlements may typically be made. With regard to the Tidmarsh litigation, I don't think it is as huge deterrent as the generic litigations (which can be settled as per above), as BP is better equipped to handle defamation cases.
0 · Reply
timfris
timfris Feb. 26 at 12:34 PM
$AUPH new indication will show up on FDA website shortly, I’d imagine.
0 · Reply
kadelawrence74
kadelawrence74 Feb. 26 at 12:31 PM
0 · Reply
bryantboy99
bryantboy99 Feb. 26 at 12:31 PM
$AUPH anybody got an updated value on our tax loss carry-over if there's an aquistion at some point? I b know they mentioned a couple hundred million in past calls.
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 26 at 12:25 PM
AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates $AUPH $IWM $IWO $IBB $VTWO https://stocktwits.com/news/equity/markets/auph-stock-gains-aurinia-pharma-q4-beat-2026-guidance-misses-estimates/cZTGaGKRIbq
0 · Reply
Work2Live
Work2Live Feb. 26 at 12:14 PM
$AUPH $98.2/12.2 = $8.05 average share price. They repurchased shares at very low price. They lowered the bar on the future guidance to ensure they keep beating estimates going forward. $135M cash flow supports development of two new indications for AUR200. This company is in BO position for any BP. The only issues preventing a BO are the patent infringement and lawsuits.
1 · Reply
VSTN
VSTN Feb. 26 at 12:12 PM
$AUPH Solid earnings and cash position. I’m comfortable adding to this one.
0 · Reply
Ballerdad1
Ballerdad1 Feb. 26 at 12:09 PM
$AUPH excellent numbers. Excited for long term shareholders!
0 · Reply
SCCT2FL
SCCT2FL Feb. 26 at 12:08 PM
$AUPH $1.60 per share earnings? Down to 112 million shares, Wall Street didn't know this and load up? No one has been buying this for months, low volume. How was this the best kept secret in the market?
1 · Reply
Latest News on AUPH
Wall Street Breakfast Podcast: FDA Executive Controversy

Nov 3, 2025, 7:31 AM EST - 4 months ago

Wall Street Breakfast Podcast: FDA Executive Controversy


Aurinia Responds to Now Retracted LinkedIn Post

Sep 29, 2025, 8:27 PM EDT - 5 months ago

Aurinia Responds to Now Retracted LinkedIn Post


Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth

Apr 26, 2025, 10:54 AM EDT - 10 months ago

Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth


Aurinia Pharmaceuticals: There's Still Time For Sales Growth

Feb 21, 2025, 4:09 PM EST - 1 year ago

Aurinia Pharmaceuticals: There's Still Time For Sales Growth


3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 1 year ago

3 Biotech Stocks With Notable Insider Buying

AZN COGT JAZZ ONC XBI ZYME


3 Small Biotech Stocks With The 'Big Mo' Right Now

Sep 19, 2024, 12:54 PM EDT - 1 year ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

CORT VRDN


Aurinia Pharmaceuticals: This Recovery Can Continue

Sep 18, 2024, 4:41 AM EDT - 1 year ago

Aurinia Pharmaceuticals: This Recovery Can Continue


Aurinia Announces Board Restructuring

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Aurinia Announces Board Restructuring


Popeye_
Popeye_ Feb. 26 at 12:36 PM
$SNAP Watchlist: $SNAP BIG NEWS: Turned into profitability last quarter. This should mark the turnaround from Snap Inc. From $5 to . https://techcrunch.com/2026/02/18/snapchat-tops-25m-subscribers-driving-companys-direct-revenue-arr-to-1b/ $IONQ Shareprice: $38 $LKNCY Shareprice: $37 $TTD Shareprice: $21 $AUPH Shareprice: $15
0 · Reply
US_Bull
US_Bull Feb. 26 at 12:35 PM
$AUPH I agree with respect to the patent litigations there is a Rule 16 telephonic conversation scheduled for March 23rd and keep in mind all the 5 litigations have been bundled up into 1 case. During or after a Rule 16 phone conversation, settlements may typically be made. With regard to the Tidmarsh litigation, I don't think it is as huge deterrent as the generic litigations (which can be settled as per above), as BP is better equipped to handle defamation cases.
0 · Reply
timfris
timfris Feb. 26 at 12:34 PM
$AUPH new indication will show up on FDA website shortly, I’d imagine.
0 · Reply
kadelawrence74
kadelawrence74 Feb. 26 at 12:31 PM
0 · Reply
bryantboy99
bryantboy99 Feb. 26 at 12:31 PM
$AUPH anybody got an updated value on our tax loss carry-over if there's an aquistion at some point? I b know they mentioned a couple hundred million in past calls.
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 26 at 12:25 PM
AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates $AUPH $IWM $IWO $IBB $VTWO https://stocktwits.com/news/equity/markets/auph-stock-gains-aurinia-pharma-q4-beat-2026-guidance-misses-estimates/cZTGaGKRIbq
0 · Reply
Work2Live
Work2Live Feb. 26 at 12:14 PM
$AUPH $98.2/12.2 = $8.05 average share price. They repurchased shares at very low price. They lowered the bar on the future guidance to ensure they keep beating estimates going forward. $135M cash flow supports development of two new indications for AUR200. This company is in BO position for any BP. The only issues preventing a BO are the patent infringement and lawsuits.
1 · Reply
VSTN
VSTN Feb. 26 at 12:12 PM
$AUPH Solid earnings and cash position. I’m comfortable adding to this one.
0 · Reply
Ballerdad1
Ballerdad1 Feb. 26 at 12:09 PM
$AUPH excellent numbers. Excited for long term shareholders!
0 · Reply
SCCT2FL
SCCT2FL Feb. 26 at 12:08 PM
$AUPH $1.60 per share earnings? Down to 112 million shares, Wall Street didn't know this and load up? No one has been buying this for months, low volume. How was this the best kept secret in the market?
1 · Reply
ATzmansto
ATzmansto Feb. 26 at 12:08 PM
$AUPH Wow fantastic earnings. I really think something is up with a BO scenario.....extremely quiet on the aur200 indications which tells me they are in negotiations. SO SOMETHING IS UP.....going to be an exiting next few months.
1 · Reply
FBP
FBP Feb. 26 at 12:08 PM
$AUPH 1.50 eps is real. Deservedly 15-20
0 · Reply
ScottyK13
ScottyK13 Feb. 26 at 12:03 PM
$AUPH great report but a little confused as I look at the financial statements they put out. Outstanding shares are down but still at 132 million. There’s one big driver of the EPS 4Q number is a $175 million income tax benefit. Not sure what that is. Hope our hero explains on the call.
0 · Reply
Martinsucks
Martinsucks Feb. 26 at 12:02 PM
$AUPH crazy how this isy only positive stock this week. Srpt and ibrx are getting slaughtered .
0 · Reply
JaneNava81
JaneNava81 Feb. 26 at 12:01 PM
1 · Reply
MireyaShumana
MireyaShumana Feb. 26 at 12:00 PM
$AUPH Analyst target price update for today @MireyaShumana
0 · Reply
chrdy
chrdy Feb. 26 at 11:59 AM
$AUPH how is this not in the hands of BP
2 · Reply
US_Bull
US_Bull Feb. 26 at 11:58 AM
$AUPH They are definitely being kept 'shut' by whoever is interested: "We have initiated a clinical study of aritinercept in one autoimmune disease and plan to initiate a clinical study in an additional autoimmune disease in the first half of 2026.” Why all the secrecy what is the disease etc. yadda yadda yadda,
1 · Reply
Martinsucks
Martinsucks Feb. 26 at 11:55 AM
$AUPH aur200?
0 · Reply
Maxwell_Smart
Maxwell_Smart Feb. 26 at 11:54 AM
$AUPH Feels like the day they got FDA approval. Will you get a calloused finger from scrolling? Bring on the zebras.
0 · Reply
Bobes
Bobes Feb. 26 at 11:54 AM
$AUPH good job auph. What a difference from 2 years ago.
0 · Reply
Mooch99
Mooch99 Feb. 26 at 11:49 AM
$AUPH Trending generative AI preview hasn't updated its worldview, it doesn't know the numbers are out. It has no idea why we're trending, it just knows that we are.
0 · Reply